3 Green Flags for CRISPR Therapeutics' Future
Despite its high-tech approach to treating hereditary diseases and cancers, the gene therapy biotech CRISPR Therapeutics (NASDAQ: CRSP) had a brutal 2021, with two-thirds of its market capitalization shaved off over the last 12 months. There's no way to sugarcoat it: The market is second-guessing whether the company can bring its portfolio of early-stage medicines through the approval process to reach commercialization.
In my view, this skepticism is healthy, and investors should consider CRISPR to be a risky purchase under the best of conditions, as it's a pioneering business in an especially challenging and much-hyped niche. But I'm still optimistic about CRISPR's potential. In particular, there are three green flags that investors should know about that dramatically increase its chances of future success.
Image source: Getty Images.
Source Fool.com
